<DOC>
	<DOCNO>NCT00006218</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness 3-AP treating patient advance cancer .</brief_summary>
	<brief_title>3-AP Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety , tolerability , toxicity 3-AP patient advanced malignancy . II . Determine maximum tolerate dose recommended phase II dose treatment patient . III . Determine pharmacokinetic parameter treatment patient . IV . Determine tumor response patient treat regimen . OUTLINE : This dose escalation , multicenter study . Patients receive 3-AP IV continuously 96 hour . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients complete response receive treatment 1 course past course complete response document ; patient partial response may receive treatment 1 year ; patient stable disease may receive treatment 6 month . During accelerated phase study , cohorts 1 patient receive escalate dos 3-AP one patient experience dose limit toxicity ( DLT ) 2 different patient experience grade 2 toxicity course . When accelerated phase end , cohort 3-6 patient receive escalate dos 3-AP maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience DLT . PROJECTED ACCRUAL : Approximately 21 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced metastatic malignancy Failed one prior standard therapy consider unlikely respond currently available therapy Measurable evaluable disease No active , untreated CNS metastasis ( stable least 2 month evidence new CNS metastasis ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL ( transfusion allow ) No bleed disorder ( except occult blood gastrointestinal cancer ) Hepatic : Bilirubin great 2.0 mg/dL ALT , AST , alkaline phosphatase great 3 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis ) PT PTT great 1.5 time ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No active heart disease No myocardial infarction within past 3 month No symptomatic coronary artery disease heart block No uncontrolled congestive heart failure Pulmonary : No moderate severe compromise pulmonary function Other : No active infection No mental deficit and/or psychiatric history would preclude study No concurrent life threaten illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 18 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No persistent chronic toxicity prior chemotherapy great grade 1 Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy Concurrent radiotherapy single site progressive disease allow first course study treatment Surgery : Not specify Other : At least 3 week since prior treatment malignancy recover No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>